Abstract
The trial reported by Stempel et al. (May 12 issue),1 which is one of five large trials conducted per requirements from the Food and Drug Administration (FDA),2 shows the safety of an inhaled long-acting beta-agonist (LABA) in patients with asthma. Concerns regarding the trial design were raised previously...
Original language | English |
---|---|
Pages (from-to) | 1096-1097 |
Number of pages | 2 |
Journal | New England Journal of Medicine |
Volume | 375 |
Issue number | 11 |
DOIs | |
Publication status | Published - 15 Sept 2016 |
Keywords
- Asthma
- Salmeterol
- long-acting beta-agonist (LABA)